Structure Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GPCR Nasdaq 2830 structuretx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Structure Therapeutics Inc.

After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching - Jun 24th, 2026 5:55 am
H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR) - Jun 17th, 2026 9:55 am
Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron - Jun 7th, 2026 9:44 pm
Does Phase 2b Oral GLP-1 Data on Aleniglipron Change The Bull Case For Structure Therapeutics (GPCR)? - Jun 7th, 2026 7:18 am
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity - Jun 5th, 2026 2:05 pm
Structure Therapeutics Announces Participation in Upcoming Investor Conferences - May 26th, 2026 2:05 pm
If Viking Therapeutics Is Acquired, Here’s Who Wins - May 26th, 2026 6:50 am
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million - May 24th, 2026 8:39 am
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter - May 24th, 2026 8:33 am
Lilly’s triple-acting obesity drug hits goal in Phase 3 trial - May 21st, 2026 3:38 am
Monashee Scales Back Its Bet on Structure Therapeutics - May 20th, 2026 1:47 pm
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - May 17th, 2026 12:42 pm
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position - May 10th, 2026 5:59 am
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights - May 7th, 2026 2:05 pm
Why Structure Therapeutics (GPCR) Is Down 7.2% After Strong Oral GLP-1 Phase 2 Data And FDA Plans - May 3rd, 2026 5:08 am
Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at - Apr 29th, 2026 7:16 am
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions - Apr 27th, 2026 2:05 pm
LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study - Apr 17th, 2026 10:53 am
3 Ways to Invest in the Growing GLP-1 Weight Loss Market - Apr 17th, 2026 9:20 am
LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill - Apr 16th, 2026 7:33 am